Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CFT7455 in Relapsed/Refractory Non-Hodgkin's Lymphoma or Multiple Myeloma
NCT04756726Phase 1Active, not recruiting
- Sponsor
- C4 Therapeutics
- Start
- Apr 2021
- Primary completion
- Sep 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of cemsidomide in non-Hodgkin lymphoma (NHL) and multiple myeloma (MM) (7 arms), sponsored by C4 Therapeutics. Primary endpoints: Safety and tolerability of cemsidomide, Safety and tolerability of cemsidomide in combination with dexamethasone and 4 more. Started Apr 2021; status: active, not recruiting.
02
Drugs
cemsidomide
03
Conditions
non-Hodgkin lymphoma (NHL)multiple myeloma (MM)
Beyond the preview
Go deeper on NCT04756726.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04756726.